Pay in 4 interest-free payments of $6.87 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
Although a number of pharmacological approaches have been investigated in recent years, few safe, therapeutically effective products have been developed
In: National Institute of Diabetes and Digestive and Kidney Diseases
GLP-1 Series Part 1: Utilization drives decline in DPP-4 inhibitors, increase in SGLT2s among competitive drug classes Contact sales for details
Impulse control disorders by dopamine partial agonists: a pharmacovigilance-pharmacodynamic assessment through the FDA adverse event reporting system
US$ 23.14
US$ 25.39
US$ 28.39
US$ 25.65
